Phase 2 N=19 Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas
Pancreatic Cancer
Primary: Dose Limiting Toxicities — 0; 0; 1; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=229 Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Pancreatic Adenocarcinoma
Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants
N/A N=399 Pancreas Resection With and Without Drains
Pancreas Tumor · Pancreatitis
Primary: 60-day ≥ Grade II Complication Rate — 72; 76 Participants — p=0.804
Phase 2 N=35 Perioperative Therapy for Resectable Pancreatic Cancer
Adenocarcinoma of the Pancreas · Stage IA Pancreatic Cancer · Stage IB Pancreatic Cancer
Primary: Median Overall Survival of Patients With Adenocarcinoma of the Pancreas — 31.6 months
Phase 2 N=48 Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
Pancreatic Cancer · Pancreatic Adenocarcinoma · Pancreas Ductal Adenocarcinoma
Primary: R0 Resection Rates in Each Cohort as Measured by Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins — 9; 9 participants with resectable PDAC
Phase 2 N=60 Vaccine Therapy Combined With Adjuvant Chemoradiotherapy in Treating Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas
Pancreatic Cancer
Primary: Overall Survival — 24.8 Months
Phase 2 N=28 Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer
Pancreatic Cancer
Primary: Median Overall Survival (OS) — 42 months
Phase 2 N=48 ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)
Pancreatic Cancer
Primary: Recurrence Free Survival — 15.6 months
Phase 2 N=32 A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma
Pancreatic Adenocarcinoma
Primary: Number of Participants With Relapse-free Survival — 3; 2 Participants
Phase 2 N=25 BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
Pancreatic Cancer
Primary: Feasibility of Adjuvant FOLFOX-A — 18 Participants
Phase 2 N=33 Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas
Pancreatic Cancer
Primary: Number of Participants With Resectability Rate — 15 Participants
Phase 2 N=39 Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery
Pancreatic Cancer
Primary: Overall Survival at 18 Months — 63 percentage of participants
Phase 3 N=200 Standardization of Surgery on the Pancreatic Cancer
Pancreatic Cancer
Primary: Survival — 37; 31 participants
N/A N=40 Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer
Resectable Pancreatic Cancers
Primary: Feasibility as Measured by Number of Participants Who Complete the Neoadjuvant Gemcitabine/Nab-paclitaxel and HIGRT Regimen — 39 Participants
Phase 2 N=49 Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)
Pancreatic Cancer
Primary: Progression-free Survival — 9.2; 8.9 months
Phase 2 N=35 Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma
Pancreatic Cancer
Primary: Local Progression-free Survival (LPFS) — 22.30801 months
Phase 3 N=546 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
Pancreatic Adenocarcinoma · Pancreatic Ductal Adenocarcinoma · Pancreatic Intraductal Papillary-Mucinous Neoplasm
Primary: Overall Survival (Percentage of Participants Alive) [Phase II] — 29.9; 28.1 months — p=0.62
Phase 2 N=25 A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients
Pancreatic Cancer
Primary: The Percentage of Patients That Underwent an R0 Resection — 52 percentage of patients
N/A N=77 Accelerated Recovery Pathway for Discharge After Surgery in Patients With Pancreatic Cancer
Pancreatic Carcinoma
Primary: Percentage of Patients Discharged by Post-operative Day 5 — 5; 28 Participants
N/A N=50 SBRT for Close or Positive Margins After Resection of Pancreatic Adenocarcinoma
Adenocarcinoma of the Pancreas
Primary: Local Progression-free Survival (LPFS) at 1-year — 85 percentage of participants
Phase 2 N=24 Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer
Pancreas Neoplasm Malignant Resectable
Primary: Frequency of R0 Resection — 11; 2 Participants
Phase 2 N=59 Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer
Pancreatic Cancer
Primary: Rate of Margin Negative Surgical Resection (R0 Resection Rate) — 88 percentage of participants
Phase 2 N=37 TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer
Pancreatic Cancer
Primary: Number of Patients With Treatment Related Serious Adverse Events — 0; 1; 0 Participants
Phase 2 N=10 Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma
Pancreatic Cancer
Primary: Biochemical Response Rate — 383; 550; 43; 53 U/mL
N/A N=40 An Analysis of Presentation and Outcome Following Treatment of Pancreatic Endocrine Neoplasms
Pancreatic Endocrine Neoplasms
Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants
Phase 2 N=32 Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
Resectable Pancreatic Cancer · Unresectable Pancreatic Cancer · Pancreatic Adenocarcinoma
Primary: CA 19-9 Normalization — 40; 13.6; 30; 50 Percentage of participants — p=0.235
Phase 2 N=37 A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer
Pancreatic Cancer
Primary: Number of Subjects Who Experience Dose Limiting Toxicities (DLTs)
Phase 2 N=22 A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma
Pancreatic Adenocarcinoma
Primary: Percentage Able to Complete Full Course of Preoperative Chemotherapy — 22 Participants
Phase 2 N=48 A Phase II Study of Neoadjuvant FOLFIRINOX
Resectable Pancreatic Ductal Adenocarcinoma
Primary: Percentage of Patients With Pathologic Complete Response — 0 percentage of participants
Phase 1 N=30 Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Percent of Patients Experiencing an Unacceptable Toxicity — 6.67; 6.67 Percentage of Participants